The value of temozolomide in combination with radiotherapy during standard treatment for newly diagnosed glioblastoma

In patients with MGMT promoter methylation, the median overall survival was 41.0 months for those receiving concomitant radiotherapy and temozolomide.

• The CCRT-TMZ group exhibited superior overall survival and progression-free survival compared to the RT → TMZ group in patients with MGMT promoter methylation.
• The median progression-free survival in the CCRT-TMZ group was 24.0 months.
• No significant difference in overall survival or progression-free survival was observed between the CCRT-TMZ and RT → TMZ groups in patients without MGMT promoter methylation.
• The findings suggest that concomitant use of temozolomide with radiotherapy may be important for glioblastoma patients with MGMT promoter methylation.
• The results are based on a retrospective analysis with a small patient sample.

AI simplified